Orforglipron helped keep weight down when used after initial therapy with an injectable, a new treatment strategy that could ...

The fresh capital provides another shot for Moderna's candidate against bird flu, which earlier this year lost its government ...

The financing follows a strategic shift for Orum, which shelved its original lead program and is now pursuing a potential ...

The company’s valuation, which surged past $40 billion this year, fell by almost a fifth on a dimmer outlook for its closely ...

The results position Takeda, which acquired its therapy in one of the industry’s larger single-drug acquisitions, to ...

The investment firm co-led a $125 million Series A round for Ambros Therapeutics, a Vivek Ramaswamy co-founded company with a ...

Recognizing the urgent need for treatment options and guided by patient insights, Pfizer scientists have discovered a way to ...

Despite being unable to declare statistical success, the company claimed its therapy showed enough promise to support moving ...

The approval could help Enhertu, which is already a multibillion-dollar seller, supplant a regimen that’s been the standard ...

Tolebrutinib, which Sanofi acquired in a $3.7 billion buyout, failed a Phase 3 study in “primary progressive” multiple ...

Lilly’s closely watched retatrutide spurred as much as 29% weight loss in a Phase 3 study, a finding that is “raising the bar ...

Using a kind of novel linker technology, the startup is developing versions of incretin and non-incretin therapies that can ...